- In late June 2026, BioCryst Pharmaceuticals said it would discontinue its internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence by the end of 2026, shifting its rare disease pipeline development toward external innovation and partnerships.
- This move marks a major change in how BioCryst sources future drug candidates, trading in-house research infrastructure for a more flexible, partner-driven model that could reshape its long-term pipeline mix.
- Next, we’ll consider how BioCryst’s decision to end internal discovery and pivot to external innovation might reshape its existing investment narrative.
Outshine the giants: these 16 early-stage AI stocks could fund your retirement
Advertisement
BioCryst Pharmaceuticals Investment Narrative Recap
To own BioCryst today, you need to believe that ORLADEYO and a focused rare disease franchise can support the business while externallydiscovery does not change the near term focus on ORLADEYO execution and key data and regulatory milestones, but it does increase uncertainty around long term research productivity and the company’s ability to replace its lead asset over time
The closure of the Birmingham Discovery Center closely ties into BioCryst’s plan to build its next wave of rare disease drugs through partnerships and in-licensing, rather than homegrown discovery. That matters when you think about upcoming catalysts for programs like navenibart and any future deals, because it puts more weight on the company’s external BD track record and capital allocation, and less on its historical discovery engine
Yet behind the recent optimism, investors should still pay close attention to how BioCryst manages its reliance on ORLADEYO and the risks around future pipeline diversification
Read the full narrative on BioCryst Pharmaceuticals (it’s free!)
BioCryst Pharmaceuticals’ narrative projects $930.1 million revenue and $131.3 million earnings by 2029. This requires 1.6% yearly revenue growth and a $589.3 million earnings increase from -$458.0 million today
Uncover how BioCryst Pharmaceuticals’ forecasts yield a $21.30 fair value, a 92% upside to its current price
Exploring Other Perspectives
Some analysts were far more optimistic before this shift, expecting revenue to reach about US$1.0 billion and earnings of roughly US$346.0 million by 2029, assuming BioCryst could keep expanding its rare disease pipeline despite the concentration risk around ORLADEYO; this new external innovation pivot might either reinforce or challenge that view, so it is worth comparing these bullish assumptions with more cautious takes to see where you stand
Explore 4 other fair value estimates on BioCryst Pharmaceuticals – why the stock might be worth over 7x more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts
- A great starting point for your BioCryst Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free BioCryst Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate BioCryst Pharmaceuticals’ overall financial health at a glance.
Searching For A Fresh Perspective?
Early movers are already taking notice. See the stocks they’re targeting before they’ve flown the coop:
- The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- We’ve uncovered the 9 dividend fortresses yielding 5%+ that don’t just survive market storms, but thrive in them.
- Capitalize on the AI infrastructure supercycle with our selection of the 52 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it
Discover if BioCryst Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition
Access Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:BCRX
BioCryst Pharmaceuticals
A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases
See The Free Research Report
Undervalued with moderate growth potential
See The Free Research Report
Similar Companies
NasdaqGS:IONS
Ionis Pharmaceuticals
NasdaqGS:BMRN
BioMarin Pharmaceutical
Market Insights
Q-Day: The risk the market forgot to repriceRichard Bowman
Finding dividends that actually lastMitchell Lawler
Watt’s left in the overcrowded power trade?Richard Bowman
Advertisement
Weekly Picks
LO
Lou_Baseneseon Giftify·3 months ago
Giftify ($GIFT): A Small-Cap Incentives Platform with More ScaleThan Its Valuation Suggests
Fair Value:US$2.561.6% undervalued
44followersusers have followed this narrative
·1commentusers have commented on this narrative
·9likesusers have liked this narrative
HA
HarishPKon lululemon athletica·29 days ago
Quantifying the Transition: Why Lululemon’s Moat Remains Intact
Fair Value:US$161.829.8% undervalued
19followersusers have followed this narrative
·2commentsusers have commented on this narrative
·8likesusers have liked this narrative
TR
tripledubon Alphabet·about 1 month ago
Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late
Fair Value:US$23057.4% overvalued
49followersusers have followed this narrative
·1commentusers have commented on this narrative
·13likesusers have liked this narrative
JO
John_Ericon Veeva Systems·6 days ago
AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability
Fair Value:US$32041.2% undervalued
28followersusers have followed this narrative
·0commentsusers have commented on this narrative
·5likesusers have liked this narrative
RecentlyUpdated Narratives
DK
DkQon Tanzania Breweries·about 3 hours ago
Tanzania Breweries will thrive with 23.62% revenue growth
Fair Value:TSh7k37.7% overvalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
SI
Simplicity_Over_Noiseon Aurinia Pharmaceuticals·about 13 hours ago
Aurinia Pharmaceuticals: Focused Execution in a Narrow but Durable Niche
Fair Value:US$16.290.4% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
ST
steffen_4h13aon Alzinova·about 15 hours ago
Fair value 7.1B Sek
Fair Value:SEK 8598.8% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
IN
Investingwillyon Mastercard·21 days ago
Mastercard: The Best Dividend Stock You’re Ignoring
Fair Value:US$75030.7% undervalued
85followersusers have followed this narrative
·1commentusers have commented on this narrative
·9likesusers have liked this narrative
BL
BlackGoaton Cerebras Systems·17 days ago
The Wafer Giant Threatening NVIDIA’s GPU Hegemony
Fair Value:US$415.5456.3% undervalued
61followersusers have followed this narrative
·3commentsusers have commented on this narrative
·10likesusers have liked this narrative
HA
HarishPKon Adobe·27 days ago
Adobe: A Probabilistic Case for Undervaluation
Fair Value:US$319.9630.9% undervalued
64followersusers have followed this narrative
·9commentsusers have commented on this narrative
·19likesusers have liked this narrative
